Renerve (ASX:RNV) Other Financing: A$-0.86 Mil (TTM As of Dec. 2025)


What is Renerve Other Financing?

Renerve ASX:RNV +1.27% Other Financing is A$-0.86 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Renerve's Other Financing for the six months ended in Dec. 2025 was A$-0.21 Mil.

Renerve's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.86 Mil.

Renerve Other Financing Historical Data

* Premium members only.

The historical data trend for Renerve's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renerve Other Financing Chart

Renerve Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Other Financing
-0.01 -0.07 -0.09 -0.67

Renerve Semi-Annual Data
Jun22 Jun23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial 0.00 0.00 -0.01 -0.65 -0.21

Renerve Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of A$-0.86 Mil mean?
Renerve (ASX:RNV) has a Other Financing of A$-0.86 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Renerve and its competitors.
Is Renerve's Other Financing too high?
Renerve's current Other Financing is A$-0.86 Mil.
How does Renerve's Other Financing compare to VRTX and REGN?
Renerve's Other Financing of A$-0.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Renerve and its competitors. Renerve's current Other Financing is A$-0.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renerve stock overvalued right now?
Renerve (ASX:RNV) has a current Other Financing of A$-0.86 Mil. The current Other Financing is A$-0.86 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Renerve (ASX:RNV), the current Other Financing is A$-0.86 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Renerve Business Description

Address 157 Heidelberg Road, Northcote, VIC, AUS, 3070
Renerve Ltd specializes in developing a range of ready-to-use products that are cleaner, safer for repairing or replacing damaged peripheral nerves, resulting in good patient outcomes. Its product candidates include NervAlign Bionic Nerve, NervAlign Nerve Graft, and NervAlign Nerve Cuff [The NervAlign Nerve Guide Matrix, The NervAlign Nerve Conduit, The NervAlign Bionic Replacement Nerve]. The company operates in New Zealand and USA. Maximum of revenue is from USA.